The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...